

Technology Advisory Committee B Interests Register

Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]

Publication Date: 15 December 2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Dr James Fotheringham	Committee Member	Direct Financial	Participated in an Advisory Board meeting for Novartis, about risk prediction tools in kidney transplantation, and honorarium was paid to directly to himself.	22/05/22	09/06/22		It was agreed this this declaration would not prevent Dr Fotheringham from participating in this discussion.
Professor Nick Latimer	Committee Member	Direct Financial	In October 2021, he gave Novartis staff a training session on survival analysis. This was not product or appraisal specific and was about methods. Novartis are listed as the manufacturer of a comparator.	19/05/22	09/06/22		It was agreed that this declaration would not prevent Professor Latimer from taking part in this discussion.
Dr Nichola Cooper	Clinical Expert	Direct Financial	Received honoraria (speaker fees and advisory boards) from Sobi, Amgen, Grifols, and Novartis.	04/08/21	09/06/22		It was agreed that this declaration would not prevent Dr Cooper from providing expert advice in this discussion.
Dr Quentin Hill	Clinical Expert	Direct Financial	Participated in consultancy or lecturing for: Alexion, Amgen, Apellis, Argenx, Grifols, Novartis, ReAlta, Sanofi,	25/05/22	09/06/22		It was agreed that this declaration would not prevent Dr Hill from

			Janssen, Immunovant and Incyte and completed Sobi's ITP clinicians for NICE survey, for which he was remunerated				providing expert advice in this discussion.
Mr Mervyn Morgan	Patient Expert	Indirect Financial	The ITP Support Association (of which Mr Morgan is CEO of) have received a grant from Swedish Orphan Biovitrum (the participating pharmaceutical company)	09/06/22	09/06/22		It was agreed that this declaration would not prevent Mervyn Morgan from providing expert advice in this discussion
Ms Rachel Russell	Appeal Panel Observer	Direct Financial	Rachel is a Pfizer employee. Although Pfizer do not have assets in thrombocytopenia, Rachel does have shares in GSK (as past employee of a company they bought out (Welcome)). GSK has a thrombocytopenia asset called Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (TA293).	07/06/22	09/06/22		It was agreed that this declaration would not prevent Rachel Russell from observing this discussion.
Dr Radha Todd	Incoming Committee A Chair	Direct Financial Interest	Radha Todd was a member of a Pfizer advisory board from September to November 2021.	02/08/22	10/08/22		It was agreed that this declaration would not prevent Dr Todd from observing this discussion.

